Fate Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 1, 2021, at 1:00 p.m. ET, followed by the BofA Securities 2021 Napa Biopharma Virtual Conference on June 15, 2021, at 5:30 p.m. ET. Investors can access live webcasts on the company's website under the 'Events & Presentations' section. Fate Therapeutics focuses on developing innovative cellular immunotherapies using its proprietary iPSC platform.

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences:

• Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 1:00 p.m. ET
• BofA Securities 2021 Napa Biopharma Virtual Conference on Tuesday, June 15, 2021, at 5:30 p.m. ET

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

When will Fate Therapeutics present at the Jefferies Virtual Healthcare Conference?

Fate Therapeutics will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:00 p.m. ET.

What is the date and time for Fate Therapeutics at the BofA Securities 2021 Napa Biopharma Virtual Conference?

The presentation at the BofA Securities 2021 Napa Biopharma Virtual Conference is scheduled for June 15, 2021, at 5:30 p.m. ET.

Where can I access the webcasts for Fate Therapeutics' investor presentations?

Webcasts for Fate Therapeutics' presentations can be accessed on their website under the 'Events & Presentations' section.

What is Fate Therapeutics focused on developing?

Fate Therapeutics is focused on developing first-in-class cellular immunotherapies for cancer using its proprietary iPSC product platform.

What types of products are in Fate Therapeutics' immuno-oncology pipeline?

Fate Therapeutics' immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cells and T-cell product candidates.